Title:
APPLICATION OF METFORMIN IN TREATMENT OF KRAS MUTANT COLORECTAL CANCER
Document Type and Number:
WIPO Patent Application WO/2021/004372
Kind Code:
A1
Abstract:
Disclosed is a marker for determining a treatment plan for colorectal cancer, the marker being a KRAS gene and/or protein; further disclosed is the use of metformin to treat patients suffering from KRAS mutant colorectal cancer. Down-regulation of the expression of metformin excretion channel MATE1 is a key mechanism of KRAS mutant colorectal cancer cells being sensitive to metformin. By reducing the transcription level of MATE1 and increasing the concentration of metformin in tumor cells, the effect of metformin in inhibiting tumor cell proliferation is enhanced.
Inventors:
GAO GUOQUAN (CN)
ZHOU TI (CN)
YANG XIA (CN)
XIE JINYE (CN)
XIA LIANGPING (CN)
HE WENZHUO (CN)
ZHOU TI (CN)
YANG XIA (CN)
XIE JINYE (CN)
XIA LIANGPING (CN)
HE WENZHUO (CN)
Application Number:
PCT/CN2020/099974
Publication Date:
January 14, 2021
Filing Date:
July 02, 2020
Export Citation:
Assignee:
UNIV SUN YAT SEN (CN)
International Classes:
C12Q1/6886; A61K31/155; A61P35/00; G01N33/574; G01N33/68
Domestic Patent References:
| WO2010028288A2 | 2010-03-11 | |||
| WO2013016714A1 | 2013-01-31 | |||
| WO2013086002A1 | 2013-06-13 |
Foreign References:
| CN110760582A | 2020-02-07 | |||
| CN109097471A | 2018-12-28 | |||
| US20170173191A1 | 2017-06-22 | |||
| CN102089007A | 2011-06-08 | |||
| CA2936345A1 | 2014-07-17 |
Other References:
GUSTAW LECH ET AL.: "Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances", WORLD J GASTROENTEROL, vol. 22, no. 5, 7 February 2016 (2016-02-07), XP055433600, DOI: 20200927221527X
Attorney, Agent or Firm:
YOGO PATENT AND TRADEMARK AGENCY LIMITED COMPANY (CN)
Download PDF: